Resverlogix Announces Voting Results From The 2017 Annual Meeting Of Shareholders

CALGARY, Alberta, Dec. 12, 2017 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”, or the “Corporation”) (TSX:RVX) announced today that, at its annual meeting of shareholders held on December 12, 2017, Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated October 30, 2017 (the “Information Circular”), which is available on SEDAR at, and on the Resverlogix website at

1.  Fixing the Number of Directors and Election of Directors

By resolution passed by ballot vote, each of the six nominees proposed as a director were elected as directors of the Corporation to hold office until the next annual meeting of Shareholders or until their successors are elected or appointed. 

The voting results for each nominee is set out below:

        Votes For Votes Withheld  Percent For Percent Withheld
Donald J. McCaffrey 33,234,615 172,543   99.48 0.52
Norma Biln 33,299,805 107,353   99.68 0.32
Shawn Lu 33,187,705 219,453   99.34 0.66
Kelly McNeill 33,302,505 104,653   99.69 0.31
Dr. Eldon Smith 33,299,805 107,353   98.68 0.32
Kenneth Zuerblis 33,319,505 87,653   99.74 0.26

2.  Appointment of Auditors

By resolution passed by show of hands, KPMG LLP, Chartered Accountants, was appointed as auditor of the Corporation to hold office until the next annual general meeting of the Shareholders and to authorize the Board to fix the auditor’s remuneration.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter:

For further information please contact:

Investor Relations
Phone: 403-254-9252
Or visit our website:

Share this post